- Home
- IVVD vs NDMO Comparison
IVVD vs NDMO Comparison
Compare IVVD & NDMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IVVD | NDMO |
|---|---|---|
| Founded | 2020 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 692.7M | 622.4M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | IVVD | NDMO |
|---|---|---|
| Price | $2.22 | $10.53 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $8.33 | N/A |
| AVG Volume (30 Days) | ★ 11.9M | 218.6K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.75% |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $50,039,000.00 | N/A |
| Revenue This Year | $103.88 | N/A |
| Revenue Next Year | $171.40 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 332.71 | N/A |
| 52 Week Low | $0.35 | $8.99 |
| 52 Week High | $3.07 | $11.24 |
Technical Indicators
Market Signals| Indicator | IVVD | NDMO |
|---|---|---|
| Relative Strength Index (RSI) | 53.88 | 49.46 |
| Support Level | $2.09 | $10.47 |
| Resistance Level | $2.60 | $10.58 |
| Average True Range (ATR) | 0.25 | 0.17 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 41.67 | 59.18 |
Price Performance
Historical ComparisonAbout IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
About NDMO Nuveen Dynamic Municipal Opportunities Fund of Beneficial Interest
Nuveen Dynamic Municipal Opportunities is a closed-end management investment company. Its investment objective is to seek total return through income exempt from regular federal income taxes and capital appreciation. A majority of its investments are made in municipal securities, the income from which is exempted from regular federal income taxes.